Reverse causality in Empa-Reg Outcome: The proverbial elephant?

被引：2
作者：
Rajput, Rajesh [1 ]
Ved, Jignesh [2 ]
机构：
[1] Pandit Bhagwat Dayal Sharma Post Grad Inst Med Sc, Dept Endocrinol, Rohtak 124001, Haryana, India
[2] Boehringer Ingelheim India Pvt Ltd, Med Affairs, 10th Floor,Hallmark Plaza, Bombay 400051, Maharashtra, India
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2017年 / 127卷
关键词：
CARDIOVASCULAR OUTCOMES; BLOOD-PRESSURE; RISK; MORTALITY; DISEASE;
D O I：
10.1016/j.diabres.2016.12.001
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：288 / 289
页数：2
相关论文
共 50 条
[11]   Influence of empagliflozin on albuminuria in the EMPA-REG OUTCOME study [J].
Ebert, Thomas .
DIABETOLOGE, 2017, 13 (07) :517-518
[12]   Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome Analysis of EMPA-REG OUTCOME using REDUCE-IT criteria [J].
Verma, Subodh ;
Kosmopoulos, Andrew ;
Bhatt, Deepak L. ;
Fitchett, David ;
Ofstad, Anne Pernille ;
Wanner, Christoph ;
Mattheus, Michaela ;
Zinman, Bernard ;
Lawler, Patrick R. ;
Leiter, Lawrence A. .
AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 15
[13]   Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial [J].
Monteiro, Pedro ;
Bergenstal, Richard M. ;
Toural, Elvira ;
Inzucchi, Silvio ;
Zinman, Bernard ;
Hantel, Stefan ;
Kis, Sanja Giljanovic ;
Kaspers, Stefan ;
George, Jyothis T. ;
Fitchett, David .
AGE AND AGEING, 2019, 48 (06) :859-866
[14]   The EMPA-REG outcome study: critical appraisal and potential clinical implications [J].
Perseghin, Gianluca ;
Solini, Anna .
CARDIOVASCULAR DIABETOLOGY, 2016, 15
[15]   EMPA-REG - the "diuretic hypothesis" [J].
McMurray, John .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2016, 30 (01) :3-4
[16]   Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics [J].
Scheen, A. J. .
DIABETES & METABOLISM, 2016, 42 (04) :224-233
[17]   Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME(R) [J].
Langslet, Gisle ;
Zinman, Bernard ;
Wanner, Christoph ;
Hantel, Stefan ;
Espadero, Rosa-Maria ;
Fitchett, David ;
Johansen, Odd Erik .
DIABETES & VASCULAR DISEASE RESEARCH, 2020, 17 (06)
[18]   Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial [J].
Verma, Subodh ;
Leiter, Lawrence A. ;
Zinman, Bernard ;
Sharma, Abhinav ;
Mattheus, Michaela ;
Fitchett, David ;
George, Jyothis ;
Ofstad, Anne Pernille ;
Kosiborod, Mikhail N. ;
Wanner, Christoph ;
Inzucchi, Silvio E. .
ESC HEART FAILURE, 2021, 8 (04) :2603-2607
[19]   Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect? [J].
Ampudia-Blasco, Francisco Javier ;
Romera, Irene ;
Arino, Bernat ;
Gomis, Ramon .
INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2017, 10 :23-26
[20]   The interim experts' counsil resolution on the EMPA-REG OUTCOME trial issues [J].
不详 .
DIABETES MELLITUS, 2016, 19 (02) :181-184
12345